Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
Khadadah FM, Cerquozzi S, Olney HJ, Fraga C, Dudebout J, Xenocostas A, Finn N, Ethier V, Savoie ML, Busque L, Jamani K, Kuruvilla P, Faught C, Leber B, Kaedbey R, Assouline SE, Kim D. Khadadah FM, et al. Among authors: olney hj. Leuk Res. 2023 Oct;133:107374. doi: 10.1016/j.leukres.2023.107374. Epub 2023 Aug 22. Leuk Res. 2023. PMID: 37657146
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.
Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP). Klil-Drori AJ, et al. Among authors: olney hj. Cancer. 2019 Feb 15;125(4):618-625. doi: 10.1002/cncr.31835. Epub 2018 Nov 13. Cancer. 2019. PMID: 30423211 Free article.
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.
Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Quebec CML Group. Klil-Drori AJ, et al. Among authors: olney hj. Am J Hematol. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29. Am J Hematol. 2017. PMID: 28670773 Free article. No abstract available.
Perioperative management of myeloproliferative neoplasms: A pan-Canadian physician survey and international expert opinion.
Szuber N, Toliopoulos P, Busque L, Cerquozzi S, Foltz L, Gupta V, Tefferi A, Vannucchi AM, Hillis C, Leber B, Maze D, Prchal J, Olney HJ, Sirhan S. Szuber N, et al. Among authors: olney hj. Am J Hematol. 2022 Dec;97(12):E466-E469. doi: 10.1002/ajh.26739. Epub 2022 Oct 3. Am J Hematol. 2022. PMID: 36151067 Free article. No abstract available.
Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group.
Simpson-Poirier K, Harnois M, Olney HJ, Sirhan S, Gratton MO, Assouline S, Laneuville P, Delage R, Mollica L, Busque L, Szuber N. Simpson-Poirier K, et al. Among authors: olney hj. Am J Hematol. 2021 Jun 1;96(6):E200-E203. doi: 10.1002/ajh.26159. Epub 2021 Mar 26. Am J Hematol. 2021. PMID: 33719144 Free PMC article. No abstract available.
Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
Wells RA, Leber B, Buckstein R, Lipton JH, Hasegawa W, Grewal K, Yee K, Olney HJ, Larratt L, Vickars L, Tinmouth A. Wells RA, et al. Among authors: olney hj. Leuk Res. 2008 Sep;32(9):1338-53. doi: 10.1016/j.leukres.2008.02.021. Epub 2008 Apr 11. Leuk Res. 2008. PMID: 18405971
33 results